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Abstract
Background: The potential of clinical interventions, aiming at reduction of preventable Adverse Drug Events
(preventable ADEs) during hospital stay, have been studied extensively. Clinical Pharmacy is a well-established and
effective service, usually consisting of full-time on-ward participation of clinical pharmacists in medical teams. Within the
current Hospital Pharmacy organisation in the Netherlands, such on-ward service is less feasible and therefore not yet
established. However, given the substantial incidence of preventable ADEs in Dutch hospitals found in recent studies,
appears warranted. Therefore, “Ward-Oriented Pharmacy”, an on-ward service tailored to the Dutch hospital setting, will
be developed. This service will consist of multifaceted interventions implemented in the Internal Medicine wards by
hospital pharmacists. The effect of this service on preventable ADEs in elderly inpatients will be measured. Elderly
patients are at high risk for ADEs due to multi-morbidity, concomitant disabilities and polypharmacy. Most studies on
the incidence and preventability of ADEs in elderly patients have been conducted in the outpatient setting or on
admission to a hospital, and fewer in the inpatient setting. Moreover, recognition of ADEs by the treating physicians is
challenging in elderly patients because their disease presentation is often atypical and complex. Detailed information
about the performance of the treating physicians in ADE recognition is scarce.
Methods/Design: The design is a multi-centre, interrupted time series study. Patients of 65 years or older,
consecutively admitted to Internal Medicine wards will be included. After a pre-measurement, a Ward-Oriented
Pharmacy service will be introduced and the effect of this service will be assessed during a post-measurement. The
primary outcome measures are the ADE prevalence on admission and ADE incidence during hospital stay. These
outcomes will be assessed using structured retrospective chart review by an independent expert panel. This
assessment will include determination of causality, severity and preventability of ADEs. In addition, the extent to
which ADEs are recognised and managed by the treating physicians will be considered.
Discussion: The primary goal of the WINGS study is to assess whether a significant reduction in preventable ADEs
in elderly inpatients can be achieved by a Ward-Oriented Pharmacy service offered. A comprehensive ADE
detection method will be used based on expert opinion and retrospective, trigger-tool enhanced, chart review.
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Harmful events caused by medication are a widely
recognised problem, both in hospital and outpatient set-
tings [1-5]. These events are known as Adverse Drug
Events (ADEs), usually defined as ‘any injury due to the
use of medication’. ADEs may occur during the normal
use of medication as a result of an unavoidable pharma-
cological effect (side effects or Adverse Drug Reactions
(ADRs)), or as a result of a medication error (preventa-
ble ADEs) [6]. Preventable ADEs are associated with
substantial morbidity, increased mortality, a longer
length of stay in the hospital and costs [7-9].
To increase medication safety, many interventions to
reduce preventable ADEs have been studied and were
found to be successful [6,10,11]. Full-time on-ward par-
ticipation of clinical pharmacists in medical teams is an
effective intervention in the hospital setting [12-15].
Nowadays, these services, often referred to as “Clinical
Pharmacy”, are routinely offered in most Anglo-Saxon
countries [16-18]. In The Netherlands however, the
Hospital Pharmacy organisation is mainly product-
oriented. Also, most of the hospital pharmacists’ time is
taken up by activities such as quality assurance of medi-
cation compounding, verification of parenteral medica-
tion prepared by pharmacy technicians, therapeutic drug
monitoring and medication logistics. In addition, the
number of Dutch hospital pharmacists is low. On aver-
age, there are fewer hospital pharmacists per 100 hospi-
tal beds (0.75) in comparison to United Kingdome
(1.42) and United States of America (14.1) [19]. As a
consequence, routine clinical activities by Dutch hospital
pharmacists are usually limited to off-ward services such
as an on-call duty for consultations and checking of
automated alerts pertaining to drug-drug interactions,
drug-drug duplications and overdosages. The disadvan-
tage of such a back-office organisation is that it gives
hospital pharmacists limited insight into the relevant
medication risks incurred by patients in the wards. The
substantial incidence of preventable ADEs in Dutch hos-
pitals found in recent studies [20-23] warrants an exten-
sion of the current off-ward clinical activities by an on-
ward pharmacy service. To maximise its effectiveness,
such a service should primarily be aimed at the highest
medication risks both at patient and organisation levels.
For efficiency reasons, an adaptation of Clinical Phar-
macy to the Dutch hospital setting is needed because
Dutch hospital pharmacists are scarce.
In this study, we choose to limit the on-ward pharmacy
service to elderly hospitalised patients using five or more
medications on the day of admission. Especially in elderly
patients, pharmacotherapy management is challenging as
polypharmacy, multi-morbidity and concomitant disabil-
ities are often present. Altered physiological functions
and cognitive decline even further increase the risk for
ADEs in this vulnerable patient group [24-26]. A number
of studies have described ADE incidence and preventabil-
ity in elderly patients in the outpatient setting and on
admission to hospitals [27-33]. However, limited data
exist regarding these outcomes in the inpatient setting
[34-36]. Furthermore, none of these studies have
addressed the extent to which ADEs detected by the
researchers were also recognised and managed by the
treating physicians in the wards. Correct diagnoses in
elderly patients are difficult to make because such
patients often present with atypical symptoms [37]. One
study found that only 51% of ADEs were recognised by
the treating physicians [38]. However, the generalisability
of these results to the inpatient setting is limited, because
only Emergency Department physicians were involved. It
thus appears that our knowledge on ADE recognition
and management in the elderly inpatients is limited and
further study is needed.
Numerous studies have investigated the effect of on-
ward pharmacy services in the elderly hospital popula-
tion by measuring surrogate end-points, such as inap-
propriate prescribing [39-42]. Only a few studies have
measured clinical outcomes such as the number of
ADEs [43,44]. However, the measurements conducted in
these studies were limited to one specific type of pre-
ventable ADEs (e.g only coagulation-related) [44] or lim-
ited in the number of participants and conducted in one
academic hospital [43]. Thus, the results of these studies
cannot readily be generalised to other hospital settings.
The WINGS study is a multicentre study, designed to
assess the reduction of ADE incidence in a high-risk
population deploying limited pharmacist resources,
focussing on ADE recognition and management by
treating physicians, using clinical outcome as an effect
measure. The on-ward pharmacy service designed in
this study will be called “Ward-Oriented Pharmacy” as
opposed to Clinical Pharmacy because hospital pharma-
cists will be attributed only part-time to this service.
The primary goals of this study are 1) to determine
the number of ADEs on admission and during hospital
stay in elderly patients, and to assess their causality, pre-
ventability, severity, recognition and management of
ADEs by treating physicians, 2) to design and imple-
ment an effective and feasible on-ward pharmacy service
for elderly patients in the Dutch hospital setting and 3)
to measure the effect of this service on the incidence of
preventable ADEs.
Methods/Design
Study design
The design is a multi-centre interrupted time series
study. The interrupted time series (ITS) model follows
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Care Review Group criteria for short time series [45].
This type of series consists of pre- and post-intervention
phases and needs to have at least three observation
points in the pre-intervention phase and three in the
post-intervention phase. Every data point needs to have
at least 30 observations. The six data points needed will
be strategically spread over pre- and post-measurement
periods. The study will be conducted during a period of
three years. An advantage of an ITS design is that it
allows for the statistical investigation of potential biases
such as secular trends in the estimate of the effect of
the intervention [46]. ITS is also more feasible than a
Randomized Controlled Trial in measuring the effect of
interventions that require organisational change to a
health care delivery system, which is the case in the
WINGS study [45].
Study setting
The participating hospitals are one academic hospital,
the Academic Medical Centre in Amsterdam, and two
non-academic hospitals, the Westfriesgasthuis Hospital
in Hoorn and the Spaarne Hospital in Hoofddorp, the
Netherlands. All internal medicine wards of these hospi-
tals participate in the study.
Study population
All consecutive patients of 65 years or older with an
expected length of stay of 24 hours or longer, using 5 or
more medications on the day of hospital admission and
admitted to an internal medicine ward during measure-
ment phases will be included. Patients admitted for
scheduled chemotherapy, radiation therapy or transplan-
tation, as well as patients transferred from another hos-
pital or from a ward other than an internal medicine
ward within the same hospital will be excluded. No
patient will be included more than once.
Intervention
During the whole study, all regular off-ward services, as
described in the Introduction section, will be offered to
Internal Medicine wards by the participating Hospital
Pharmacy departments. During the intervention period,
a designed Ward-Oriented Pharmacy service will be
added to regular off-ward pharmacy services offered to
all Internal Medicine wards of the participating hospi-
tals. A Ward-Oriented Pharmacy service will consist of
multifaceted interventions such as pharmacotherapy
education, writing and implementation of drug proto-
cols, face-to-face pharmacotherapy guidance of prescri-
bers, participation in ward-rounds and medication
reviews. Multifaceted interventions are reported to be
more effective than single interventions, especially when
these are complementary and not overly complex [47].
To promote implementation of a Ward-Oriented Phar-
macy service, the three participating hospitals can
choose different types of interventions to include in this
service.
To be able to choose efficient interventions and to
design a feasible Ward-Oriented Pharmacy service, the
following steps will be taken:
1) An analysis of preventable ADEs based on the pre-
measurement results will be conducted to identify most
frequent medication risks in elderly inpatients. These
risks will be categorised in patient-related medication
risks and organisational medication risks. Patient-related
medication risks refer to patients’ characteristics, for
example use of specific medication or the presence of
specific co-morbidities, which might be associated with
a higher risk for preventable ADEs. Organisational risks
refer to ward characteristics, for example the extent to
which pharmacotherapy guidelines or protocols are
available and the level of existing knowledge and educa-
tion. Lacking or insufficient pharmacotherapy guidelines,
protocols or knowledge could entail a higher risk for
preventable ADEs.
2) The results from step one will be presented to a
multidisciplinary group consisting of Internal Medicine
and Hospital Pharmacy staff members and residents of
all three participating hospitals. These groups will prior-
itise risks and choose interventions tailored to local
needs and possibilities to design a specific Ward-
Oriented Pharmacy service. Tools and strategies like
B o w - T i er i s ka n a l y s i sa n dt h eS w i s sC h e e s em o d e l
[48,49] will be used to structure this process.
3) To further assure a successful implementation pro-
cess, a finally designed Ward-Oriented Pharmacy service
will be presented to all personnel in the participating
departments. A one-month introduction period will be
used to fine-tune the interventions. To keep the partici-
pating departments informed about the progress of the
study, periodic evaluations will be planned and a news-
letter will be distributed. After 7 months we expect the
implementation of a Ward-Oriented Pharmacy service
to be finalised.
Study Outcomes
The primary outcomes of this study are 1) the number,
severity and preventability of ADEs present at admission
calculated per 100 hospitalisations, 2) the number,
severity and preventability of ADEs during hospital stay
calculated per 100 hospitalisations, 3) the percentage of
ADEs recognised and appropriately managed by the
treating physicians.
The secondary outcomes of this study are 1) the num-
ber of medication errors per number of medication
orders and 2) the number of readmissions within three
months after the index hospitalisation.
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be implemented, additional secondary outcomes will be
measured to monitor the implementation of these speci-
fic interventions. For example, pharmacotherapy consul-
tations given by hospital pharmacists on the wards can
be monitored by recording the number of advices given
to the physicians and nurses.
Data collection and outcome assessment
The flow charts of the data collection process and the
outcome assessment process are shown in Figures 1 and
2 and have been adapted from previous studies [50,51].
First, trained research nurses and pharmacy students
will collect all information available about the index hospi-
talisation of included patients, after discharge of each
patient. All charts, laboratory results, rapports of diagnos-
tic procedures and medication prescriptions will be
assembled. A Case Report Form (CRF) will be completed
for every included patient. In the CRF, a selection of ADE
triggers is listed and can be checked off when applicable.
The selection of included ADE triggers was based on avail-
able trigger tools [52,53] and expert opinion.
Second, copies of the gathered information and the
CRF of all included patients will be presented to two
independent experts: a senior specialist in Internal Med-
icine and a senior clinical pharmacist specialised in ger-
iatrics (LA and CS respectively). The two experts will
first review the presented information independently
from each other. This first review is an implicit process
b a s e do ne x p e r tj u d g m e n t ,w h i c hi ss t i l lt h e“gold stan-
dard” in adverse events determination [52]. In this study
we use implicit judgment of a pharmacist and physician
team because their knowledge has shown to be comple-
mentary [54,55].
Third, the two experts will discuss their findings in an
expert panel meeting. During this second review, the
causality between the adverse events found during the
first review and commission or omission of medication
will be assessed. Only ADEs for which the experts meet
consensus on causality will be recorded and subse-
quently assessed on preventability, severity and, when
applicable, on type of medication error. If consensus
cannot be reached, the opinion of a third expert will be
sought.
For the ADE causality assessment used in the second
review, we developed a structured method based on the
World Health Organization - Uppsala Medical Centre
(WHO-UMC) system [56]. The causality will be scored
5HVHDUFKQXUVHVSKDUPDF\VWXGHQWV
&RSLHVRIDERYHGHVFULEHGLQIRUPDWLRQLIDYDLODEOH &DVH5HSRUW)RUP
,QGHSHQGHQWUHYLHZE\H[SHUWV
([SHUWSDQHOPHHWLQJ
$'(VPHGLFDWLRQHUURUVH[FOXVLRQV
&ODVVLILFDWLRQ)LJXUH
/DERUDWRULHV
 EORRGFKHPLVWU\
 PLFURELRORJ\DQGYLURORJ\
 SDWKRORJ\
'LDJQRVWLFV
SURFHGXUHV
V F R S H V
V F D Q V
3UHVFULSWLRQV
& 3 2 (  G D W D 
 ZULWWHQPHGLFDWLRQRUGHUV
 KRPHPHGLFDWLRQKLVWRULHV
&KDUWV
 GLVFKDUJHVXPPDULHVDQGOHWWHUV
 SK\VLFLDQSURJUHVVQRWHV
 QXUVLQJSURJUHVVQRWHV
 PXOWLGLVFLSOLQDU\SURJUHVVQRWHV
Figure 1 Process of data collection and outcome assessment.
1 CPOE, Computer Physician Order Entry
2 ADEs, Adverse Drug Events
(preventable and non-preventable)
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there is a causal relationship between adverse event and
a drug), probable/likely (> 65-90% certainty that there is
a causal relationship between adverse event and a drug),
possible (33-65% certainty that there is a causal relation-
ship between adverse event and a drug). ADEs with 32%
or less certainty in causality will not be recorded and
therefore not further assessed. The severity of ADEs will
be scored according to the Common Terminology Cri-
teria for Adverse Events version 3.0 (CTCAEv3) devel-
oped by the U.S. National Cancer Institute [57].
CTCAEv3 is a descriptive terminology used to report
adverse events in many clinical trials. For each ADE, a
5-points scale of seriousness is included: mild, moderate,
severe, life-treating, fatal.
An innovative item in our ADE assessment is the
determination of recognition and management of ADEs
by the treating physicians during hospitalisation. For
every ADE present on admission or occurred during the
index hospitalisation, the experts will assess if it was
recognised by the treating physicians in the Internal
Medicine wards. When applicable, the experts will assess
whether the chosen management was timely and suffi-
cient to stop or preclude further harm.
ADEs that will be included in this study are shown in
Figure 3. The index hospitalisation is the hospitalisation
sampled. ADEs will be included if they were present on
admission or occurred during the index hospitalisation.
For each included patient, one of the experts (CS) will
also score a predefined set of medication errors that
occurred during the index hospitalisation, but did not
cause patient harm. Medication errors will be classified
according to the Dutch Central Medication Incidents
Registration.
Definitions
The definitions used in this study were adapted from
the Glossary of Terms Related to Patient and Medica-
tion Safety by Expert Group On Safe Medication Prac-
tices [6].
Adverse Drug Event (ADE) is any injury occurring dur-
ing the patient’s drug therapy and resulting either from
appropriate care, or from unsuitable or suboptimal care.
ADEs include non-preventable A d v e r s eD r u gR e a c t i o n s
(ADRs) during normal use of medication, and any harm
secondary to a medication error (preventable ADEs),
both errors of omission and commission will be
included. An ADE can result in different clinical out-
comes, for example: abnormal laboratory values, wor-
sening of the existing disease, lack of any expected
disease improvement, or outbreak of new symptoms or
diseases.
Harm: temporary or permanent impairment of the
physical, emotional, or psychological function or struc-
ture of the body and/or pain resulting there from
requiring intervention. In this study also abnormal
laboratory values will be counted as harm.
Medication error: any preventable event that may
cause or lead to inappropriate medication use or patient
harm while the medication is in the control of the
health care professional or patient. Such events may be
related to professional practice, health care products,
procedures, and systems, including prescribing; order
communication; product labelling, packaging, and
nomenclature; compounding; dispensing; distribution;
administration; education; monitoring; and use.
Sample size calculation and data analysis
The power-calculation for this study was based on the
expected incidence of 15 ADEs per 100 hospitalisations
and a clinically relevant 50% reduction by a Ward-
Oriented Pharmacy service in the post-measurement
period. This assumption was made based on the findings
of two controlled studies that assessed active clinical
pharmacists participation in medical teams on the
wards, showing a reduction of 66% and 78% respectively
[12,13]. To be able to identify a significant reduction
from 15 ADEs to 7.5 ADEs per 100 hospitalisations, 496
patient admissions are needed, equally divided between
pre- and post-measurement period (a =0 , 0 5a n db =
0,8). This sample size enables to identify a reduction of
19 ADEs or more from the expected 38 ADEs in 248
admissions during the pre-measurement period.
Event
Present at admission
OR
During hospital stay
Causality: nearly certain ADE, 
probable/likely ADE, possible ADE
Severity: mild,  moderate, severe, life-
threatening,  fatal
No medication 
error
ADR1
Medication error
Preventable ADE2
Follow-up: recognised and managed, recognised but 
not timely or sufficiently managed, not recognised
Stage and type
Figure 2 Process of outcome classification and scoring.
1 ADR,
Adverse Drug Reaction, non-preventable
2 ADE, Adverse Drug Event
(preventable and non-preventable)
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characteristics for the three participating hospitals and
to check for any imbalance in variables between pre-
and post-measurement groups. By comparing the pre-
and post-measurement periods, the effect of a Ward-
Oriented Pharmacy service will be analysed using a sui-
table generalised linear model for a short interrupted
time series. Adjustment will be made for any case mix
imbalances between pre- and post-measurement periods
and background trend in the ADE rate over time.
Exploratory analyses are also planned to examine the
effect of factors like age, sex, length of hospital stay,
Charlson Co-morbidity Index Score [58], renal function
on the primary and secondary outcomes. For this pur-
pose unadjusted univariate and adjusted multivariate
Poisson regression analyses are planned.
Quality assurance
To ensure quality of data collection, research nurses and
pharmacy students will be trained by an experienced
member of the research team (JK) to collect the data and
how to complete the CRFs. Before the start of the study,
research nurses and pharmacy students involved in data-
collection will test whether the designed CRF is explicit,
comprehensive, and user-friendly. When necessary, the
CRF will be adjusted to improve it and a manual will be
written to guide the data-collectors during the whole
process. This manual will also be tested to assure that it
is explicit, comprehensive, and user-friendly.
Before the start of the study, the structured outcome
assessment by the expert panel will be tested by the
experts on a sample of 10 patients to ensure that it is
explicit, comprehensive and user-friendly. If necessary,
the assessment will be adjusted to improve these charac-
teristics. Furthermore, the intra-rater and inter-rater
reliability of the assessment process by the expert team
will be assessed. For this purpose the kappa statistic ()
will be calculated. A kappa value of 0.00 will be consid-
ered as poor agreement, 0.01-0.20 as slight agreement,
0.21-0.40 as fair agreement, 0.41- 0.60 as moderate
agreement, 0.61-0.80 as substantial agreement, and 0.81-
1.00 as almost perfect agreement [59].
Study organisation and management
The research protocol was submitted to the Medical
Ethics Committee of the Academic Medical Centre
(AMC) before the start of the study. The Medical Ethics
Committee of AMC judged the protocol as not needing
an approval because the Dutch Medical Research Invol-
ving Human Subjects Act (WMO) does not apply to the
WINGS study. In this research, we use a retrospective
chart review to evaluate the effect of an intervention
aimed at quality improvement. Therefore, the integrity
of the patients is not influenced. All patient data will be
analysed anonymously by coding every patient by a 6-
digit number.
In every hospital a group of representatives of the
Internal Medicine Department and Hospital Pharmacy
Department has been formed. The main investigator
(JK) and project manager (LL) will meet at least
monthly with these representatives to oversee the pro-
gress of the study.
HOME
General Practitioner/Outpatient Clinic
Medication is 
prescribed
HOSPITAL
Specialist/Resident
Patiënt is taking medication
Event is timely recognised, but actions taken are not sufficient
Event is not timely recognised, but actions taken are sufficient
Event is not recognised, no actions taken
Indicated 
medication is 
NOT 
prescribed
Omission Event
Event
OR
Event is recognised, actions are timely and sufficient
OR
OR/AND
OR
Medication
is
prescribed
Event is timely recognised, but actions taken are not sufficient
Event is not timely recognised, but actions taken are sufficient
Event is recognised, actions are timely and sufficient
Patiënt is taking medication
Omission Event
Event
OR
Indicated 
medication 
is NOT 
prescribed
Event is not recognised, no actions taken
OR
OR/AND
OR
INDEX HOSPITALISATION
Figure 3 ADEs included in the study.
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cist Coordinated ADE Reducing Efforts For Use in all
Levels of healthcare) research programme, based on a
cooperation of Leiden University Medical Centre, Aca-
demic Medical Centre Amsterdam, University Medical
Centre Groningen and University Medical Centre
Utrecht/Utrecht University. Within this programme,
interventions are studied that are aimed at promoting
medication safety in hospital and outpatient settings.
Discussion
Clinical Pharmacy as practised in Anglo-Saxon countries
has shown to be successful in reducing preventable
ADEs in various hospital patient populations [12-15]. In
this study, the effect of a Ward-Oriented Pharmacy ser-
vice on preventable ADEs in elderly inpatients will be
investigated. The Ward-Oriented Pharmacy service is an
on-ward pharmacy service based on the successful Clini-
cal Pharmacy practice but tailored to the Dutch hospital
setting. The Ward-Oriented Pharmacy service will
include multifaceted interventions implemented in Inter-
nal Medicine wards by hospital pharmacists. Adapting
Clinical Pharmacy practice to the Dutch hospital setting
is necessary, because Clinical Pharmacy entails a full-
time participation of clinical pharmacists in medical
teams on the wards, a time investment that is not feasi-
ble within the current organisation of Hospital Phar-
macy in the Netherlands. This applies also to many
other European countries [19]. Moreover, active on-
ward participation of pharmacists in medical teams is a
practice Dutch physicians are not familiar with. This
could raise barriers that also need to be considered.
T h er e s u l t so ft h eW I N G Ss t u d yw i l la d di n s i g h ti n t o
the effectiveness of Ward-Oriented Pharmacy on the
reduction of ADEs in elderly inpatients. Also the extent
to which this service is feasible in the Dutch setting will
be explored. By measuring ADEs across the process of
admission and subsequent hospitalisation, the extent to
which ADEs are recognised and appropriately managed
by treating physicians will be investigated. Especially in
elderly patients, ADE awareness is essential to be able to
practice the safest possible pharmacotherapy [37].
The method of data collection and chart review used
in the WINGS study differs from the standard trigger-
tool based chart review method used in other ADE stu-
dies [35]. According to the standard method, only charts
with one or more triggers are subjected to further
review by a physician. Therefore, only a selection of
ADEs can be scored and this selection depends on the
predefined selection of triggers used in the first step of
data collection and examination procedure. In contrast,
t h et r i g g e r - t o o lb a s e dC R Fi nt h i ss t u d ys e r v e so n l ya s
an aid to help the experts. Trigger-tools have shown to
be able to increase the detection of ADEs and can be
computerised or used manually [60]. We will use man-
ual screening for ADE triggers in patient files instead of
electronic trigger-tools, because by the manual method,
the narrative information, such as progress notes or dis-
charge letters, can be screened. Symptoms like constipa-
tion, dizziness, falls and hypotension are examples of
ADE triggers in narrative information sources. By sub-
jecting all included patients to further review and apply-
ing the above described method, a more sensitive ADE
assessment by the experts is expected. In our setting,
where the magnitude of medication risks in elderly inpa-
tients is unclear, such a comprehensive approach is
needed to gain detailed insight into this problem. The
time-consuming character of our method is not a bar-
rier, because it is used for research purposes.
In the WINGS study, the primary outcome (ADE) is
assessed by using a combination of implicit expert judg-
ment with structured causality assessment based on the
WHO-UMC system [56]. Because the WHO-UMC sys-
tem was developed for ADRs causality assessment, we
added or discarded items to design a causality assess-
ment strategy for ADEs and therefore assessment of
ADRs and preventable ADEs. Furthermore, both errors
of omission and commission are considered as causes of
preventable ADEs in our assessment [50].
The expert judgment is the most popular and most
widely used method, even given limitations like lack of
reproducibility, poor inter- and intra-rater agreement
and a lack of standardised clinical evaluation. Algo-
rithms for ADR causality assessment have been devel-
oped to overcome the limitations of expert judgment
[61]. However, as mentioned before, ADE assessment
in elderly patients could be complicated by factors like
multi-morbidity, polypharmacy and atypical presenta-
tion of diseases. Therefore, opinion of clinically
experienced reviewers, who are able to weigh drug
causation considering all these factors, is essential. In
order to do so, less flexible and less specific algo-
rithms are not suitable in this study. It has also been
shown that reproducibility of results from the use of
such algorithms can drastically decrease, yielding low
inter-rater variability, because clinical judgment is
always necessary to be able to answer all the questions
included [61].
To improve the validity of the method used in this
study, we have taken three measures:
1) by using a CRF we help the experts to standardise
their clinical evaluation, 2) by combining implicit review
followed by structured causality assessment we lower
the subjectivity of the expert’s decisions 3) by deploy-
ment of the same expert team in ADE assessment in the
pre- and post-measurement phases the problem of low
inter-rater agreement seen in studies using expert judg-
ment can be partly overcome [55].
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